Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787046 | 0.93 | CDK2 (0.38) | NAMPTCHRM1AURKACCNA2CDK2 | |
| SCHEMBL6793766 | 0.92 | CCNA2 (0.39) | NAMPTAURKACCNA2CDK2CCNA1 | |
| SCHEMBL6794733 | 0.91 | BRAF (0.34) | NAMPTGSK3B | |
| SCHEMBL1659385 | 0.86 | CDK2 (0.34) | NAMPTAURKACCNA2CDK2CCNA1 | |
| Trifluoroacetic Acid SCHEMBL6796768 | 0.85 | CCNC (0.32) | ALDH1A1CHRM1AURKACCNA2CDK2 | |
| SCHEMBL6793304 | 0.85 | KDM4C (0.37) | AURKACCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL1658167 | 0.84 | CDK2 (0.42) | AURKACCNA2CDK2CCNA1 | |
| SCHEMBL6793189 | 0.84 | CDK2 (0.35) | AURKACCNA2CDK2CCNA1 | |
| Trifluoroacetic Acid SCHEMBL6791881 | 0.84 | CHRM2 (0.35) | CHRM1AURKACCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL4263501 | 0.84 | CYP3A4 (0.34) | NAMPTCHRM1AURKACCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | NAMPT 658/4885GSK3B 447/4885IKBKE 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.